Data from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma

• DOI: 10.1158/1078-0432.c.6528354.v1
• Publication Date: 2023-04-01T01:35:25Z
• Authors: Robyn D. Gartrell; Douglas K. Marks; Emanuelle M. Rizk; Margaret Bogardus; Camille L. Gérard; Luke W. Barker; Yichun Fu; Camden L. Esancy; Gen Li; Jiayi Ji; Shumin Rui; Marc S. Ernstoff; Bret Taback; Sarabjot Pabla; Rui Chang; Sandra J. Lee; John J. Krolewski; Carl Morrison; Basil A. Horst; Yvonne M. Saenger
• Keywords: Cut-off

<div>AbstractPurpose:<p>Biomarkers are needed to stratify patients with stage II–III melanoma for clinical trials of adjuvant therapy because, while immunotherapy is protective, it also confers the risk severe toxicity. We previously defined and validated a 53-immune gene immune profile (MIP) predictive both distant metastatic recurrence disease-specific survival (DSS). Here, we test MIP on third independent population.</p>Experimental Design:<p>A retrospective cohort 78 primary was analyzed using NanoString assay measure expression 53 target genes, score calculated. Statistical analysis correlating DSS, overall survival, recurrence, metastasis-free interval performed ROC curves, Kaplan–Meier standard univariable multivariable Cox proportional hazards models.</p>Results:<p>MIP significantly distinguished from those without curve (AUC = 0.695; <i>P</i> 0.008). high- low-risk groups based cutoff by this find that correlates DSS 0.719; 0.004 AUC 0.698; 0.004, respectively). Univariable regression reveals high-risk (<i>P</i> 0.015; HR 3.2).</p>Conclusions:<p>MIP identifies low death may constitute tool enrollment in trials.</p></div>